Novo Nordisk Faces Worst Day Since 2002 As Oral Weight Loss Drug Disappoints
Novo Nordisk, a global leader in diabetes care and weight management, has recently found itself in a challenging position following the disappointing trial results of its oral weight loss drug. The news has sent shockwaves through the pharmaceutical industry and investor community alike, leading to significant stock price fluctuations. As the company navigates this turbulent … Read more